Chimeric ICAM-1/IgA immunoadhesins effectively neutralize and disrupt human rhinoviruses at nanomolar concentrations, suggesting potential as a therapeutic agent.
No takes yet. Share an insight, caveat, or question.
Chimeric ICAM-1 agents merit further HRV study; animal data leave open clinical translation and efficacy.
Martin et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: